Chicken infectious anemia virus (CIAV) is a unique infectious agent with an amino acid composition that has been found to be remarkably conserved even in isolates from different parts of the world. We have characterized field isolates of CIAV which vary significantly in terms of their abilities to replicate in culture, demonstrating a biological difference between isolates. Two sublines of MDCC-MSB1 cells that differ in their abilities to support CIAV were identified. In the MSB1(S) subline the CIA-1 isolate of CIAV was found to be less cytopathogenic than the prototype Cux-1(C) isolate; the MSB1(L) subline, which supports Cux-1(C) replication, was found to be nonpermissive for CIA-1. Alignments of the VP1 sequences of previously examined isolates with those of the field isolates CIA-1 and L-028 and the culture-adapted ConnB isolate revealed a previously unreported hypervariable region spanning amino acid positions 139 to 151. Chimeras of Cux-1(C) and CIA-1 were constructed to examine the potential for this region to affect cytopathogenicity. Transfer of a 316-bp region of Cux-1(C) open reading frame 1 into CIA-1 produced a virus with a cytopathogenic profile typical of Cux-1(C), indicating that one or both of the amino acid differences at positions 139 and 144 affect the rate of replication or the spread of infection. Transfection experiments with additional chimeras indicated that the inability of CIA-1 to replicate in MSB1(L) cells is mediated by a larger region of the genome which contains the hypervariable region in addition to upstream amino acid differences. Analysis of chimeras excluding the entire region of open reading frame 1 suggested the presence of a secondary mediator in the progression of infection in culture that was localized to a region containing a single nucleotide difference which results in amino acid differences in both VP2 (V-153) and the nuclear localization signal of VP3 (C-118). Immunofluorescence assays indicated an increased cytoplasmic distribution of VP3 and a general lack of VP3-associated apoptotic bodies in infections of CIA-1 and chimeras containing V-153 or C-118, as opposed to a primarily nuclear distribution and association with well-formed apoptotic bodies in Cux-1(C)-infected cells.
Chicken infectious anemia virus (CIAV; also called chicken anemia virus) is a member of the newly categorized Circoviridae, a family of circular negative single-stranded DNA viruses that also includes the porcine circovirus and the beak and feather disease virus of parrots (25) . Although these viruses are grouped together on the basis of a common genome form, no similarities in amino acid composition, open reading frame (ORF) arrangement, or transcriptional machinery have been identified (15) . Recently, the 2.3-kb genome of the Cux-1 strain (27) was sequenced (14) and found to have three partially overlapping ORFs, potentially encoding proteins of 51.6 (VP1), 24 .0 (VP2), and 13.6 (VP3) kDa. No relationship with other viruses has been established at the amino acid level, and at present CIAV is considered to be a unique infectious agent.
CIAV in young chickens causes clinical disease characterized by anemia, hemorrhages, and atrophy of the thymus and bone marrow. The virus replicates in lymphoid cells and is cytopathic (15, 29) . Cell death is believed to occur by apoptosis following expression of VP3 (8, 16) . Lymphocyte depletion results in immunosuppression and increased susceptibility to various viral and bacterial pathogens (26) . Outside of the host, CIAV can be propagated in embryonated eggs and lymphoblastoid cell lines but not in chicken embryo fibroblasts, chicken kidney cells, or other primary cells (28) . Most molecular studies on the virus have used suspension cultures of the Marek's disease virus-transformed chicken T-cell line MDCC-MSB1 for propagation (1) .
Previous studies have identified only a single serotype (12, 29) , and only minor variations in predicted amino acid sequences have been noted in isolates taken from different parts of the world (5, 9, 14, 17) . For these reasons the amino acid composition of CIAV is considered to be highly conserved. However, we have identified field isolates that do not replicate in some MDCC-MSB1 sublines and that show an altered cytopathogenicity in other sublines, indicating that there are biological differences among isolates. This suggests the potential for differences in host-related pathogenicity and cell tropism. Using nucleotide sequence information from these isolates we have identified regions of variability and constructed chimeric virus clones with replacements of these regions. Transfection experiments using permissive and nonpermissive cell lines were used to identify regions that have an impact on the biological properties of the virus.
MATERIALS AND METHODS
Cell lines and viruses. Two divergent sublines of the Marek's disease virustransformed T-lymphoblastoid cell line MDCC-MSB1 (1) were used for analysis. MSB1(L) cells were provided by R. L. Witter, USDA Regional Poultry Research Laboratory, East Lansing, Mich., and MSB1(S) cells were provided by G. Thiry, Solvay Animal Health, Mendota Heights, Minn. Cells were cultured in Leibovitz's L-15-McCoy's 5A medium (2) supplemented with 10% fetal bovine serum (LM-10), at 40ЊC in a 5% CO 2 atmosphere.
The CIA-1 strain (11) was isolated in 1988 from a farm in Delaware, and the L-028 strain was isolated in 1992 from a farm in New York (10a). Liver homogenate stocks of CIA-1 and L-028 were prepared following inoculation of day-old chicks as described previously (11) . Cux-1(C) (3), isolated in Cuxhaven, Germany, and ConnB, a farm isolate from Connecticut, were provided by C. R. Wellenstein, SPAFAS Inc.; both isolates were of unknown passage history. Cux-1(C) and ConnB were propagated in the MSB1(L) subline as described previously (7, 28) . CIA-1 and Cux-1 stocks were titered by serial dilution on MSB1(S) cells by the method of Reed and Muench (18) .
Cloning of CIAV and chimera construction. Virion DNA from MSB1(L) cell culture medium was the template for the Cux-1(C) and ConnB isolates, and virion DNA from liver tissue was used for amplification of field isolates. DNA was prepared by proteinase K digestion and phenol-chloroform extraction. Genomes were amplified by PCR as two EcoRI-BamHI fragments and cloned into pBluescript II KS Ϫ (Stratagene, La Jolla, Calif.) as described elsewhere (22) . The fragments of approximately 1,500 and 800 bp were ligated at the terminal BamHI sites to obtain full-length clones. To facilitate chimera construction, the CIAV inserts were subsequently removed with KpnI and SmaI and ligated into pBS KS/Delta BamHI-SacI, a vector with the BamHI-to-SacI region within the pBS KS Ϫ multiple cloning site deleted. For the construction of chimeras, all manipulations of DNAs were performed according to standard protocols (19) . Nucleotide numbering refers to the published sequence for Cux-1(N) (14) . pCIA/Cux N-B and pCux/CIA N-B were assembled by digestion of full-length pCux-1(C) and pCIA-1 with NheI (nucleotide 1191) and BamHI (nucleotide 1508) and by switching of the excised fragments. pCIA/Cux S-B and pCux/CIA S-B were constructed by utilization of the SacI (nucleotide 864) and BamHI (nucleotide 1508) sites. pCux/CIA B-S, pCIA/ Cux B-S, pCux/CIA S-S, and pCIA/Cux S-S were generated with either BsmI (nucleotide 642) or SacI (nucleotide 864) at unique sites within the viral genome and at the multiple cloning site SmaI. pCIA/Cux K-N and pCux/CIA K-N were constructed with the multiple cloning site KpnI and the internal NheI site (nucleotide 1191).
Sequence analysis. DNA sequences were determined by the dideoxy chain termination method (20) with synthetic primers and analyzed with Genetics Computer Group (Madison, Wis.) software (version 7.3) (6) .
DNA preparation and transfection. Viral DNAs were prepared for transfection by digesting 5 g of plasmid DNA with EcoRI to release the CIAV insert and with SmaI and KpnI to cut at unique sites within the pBS KS Ϫ multiple cloning site. Restriction products were purified with a silica-based column (Qiagen, Chatsworth, Calif.) and ligated overnight in a 50-l volume. Products were extracted with phenol-chloroform, ethanol precipitated, and resuspended in 50 l of H 2 O. Aliquots were examined by agarose gel electrophoresis to verify consistent ligation. MSB1(S) or MSB1(L) cells were washed and resuspended in LM medium without fetal bovine serum to a final concentration of 2 ϫ 10 6 in 700 l. Standardized ligation products were transfected by electroporation in 0.4-cm-gap cuvettes at 300 V and 500 F. Cells were immediately transferred to 25-cm 2 flasks containing 5 ml of LM-10 and passaged every 2 to 4 days. Five hundred nanograms of pRc/RSV-lacZ (Invitrogen, San Diego, Calif.) was included with each CIAV DNA sample in the MSB1(S) transfection experiment to verify transfection efficiency. At 24 to 48 h posttransfection cells were air dried to glass slides and fixed with acetone-methanol (50:50). Slides were incubated in 5 mM potassium ferricyanide-5 mM potassium ferrocyanide in Tris-buffered saline with 50 g of X-Gal (5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside) per ml for up to 1 h. Blue cells were scored as a percentage of total cells.
Immunofluorescence assay. Cells were washed and resuspended in Tris-buffered saline and plated on 12-well slides, air dried, and fixed with acetonemethanol (50:50). Slides were incubated with the CIAV VP3-specific monoclonal antibody 51.3 (3) for 30 to 60 min at room temperature, washed for 10 min, and incubated for 30 min with fluorescein isothiocyanate-conjugated rabbit antimouse immunoglobulin G antibody. Following a second wash, slides were mounted with 90% glycerol-3% 1,4-diazabicyclo-[2.2.2]octane-100 mM TrisHCl (pH 8.6).
Nucleotide sequence accession numbers. The sequence of CIA-1 has been submitted to GenBank under accession number L14767. The ORF1 sequences of ConnB and L-028 have been submitted under accession numbers U69548 and U69549, respectively.
RESULTS
Replication of CIA-1. The CIA-1 isolate of CIAV is a field isolate with distinguishing characteristics in culture that include the inability to replicate in some cell lines normally considered to be CIAV permissive. Repeated attempts to adapt CIA-1 to the MSB1(L) subline, CU147, a Marek's disease virus-transformed chicken T-cell line, and CU205 (21), a reticuloendotheliosis virus-transformed chicken T-cell line, have been unsuccessful. In contrast, all of these cell lines support the replication of the prototype Cux-1(C) isolate (results not shown). We identified a subline of MDCC-MSB1 [MSB1(S)] that will support the replication of CIA-1, although the rate of spread in culture is lower than that of Cux-1(C). A second field isolate, L-028, was tested for the ability to replicate in both MSB1(L) and (S) sublines, and as with CIA-1, productive infections developed only in the MSB1(S) subline. In typical comparisons of Cux-1(C) and CIA-1 infections, Cux-1(C) cultures had levels of infected cells ranging from 60 to 90% at 4 to 6 days postinfection (p.i.) while CIA-1 infections normally required 10 to 14 days before comparable levels of VP3-antigen-positive cells were observed. Examination of cultures infected with equivalent doses of infectious virions showed that the number of Cux-1(C)-infected cells increased exponentially while that of positive cells in the CIA-1 infection increased linearly (Fig. 1) . Most notably, at 3 days p.i. both cultures were roughly equivalent, with 0.08% antigen-positive cells for CIA-1 and 0.10% for Cux-1(C), but at 5 days p.i. only 0.55% of cells were positive in the CIA-1 culture compared with 64.0% in the Cux-1(C) culture.
A phenomenon adding to the complexity of this analysis was the appearance of CIAV-resistant subpopulations of cells. As can be observed in Fig. 1 , total cell death was not achieved in either the Cux-1(C)-or CIA-1-infected culture. In experimental infections performed over the course of these studies, the percentages of antigen-positive cells often increased to 30 to 80% before falling and then entering a period of fluctuation, which appears to suggest that both cell and virus populations predominate at different times. However, in some cases there was complete or almost complete cell death, most commonly with rapidly replicating isolates, such as Cux-1(C), and particularly when high-titer stocks were used. Subpopulations arising from Cux-1(C)-infected cells that were passaged until antigen- Sequence comparison of CIAV isolates. Differences in the abilities of the field isolates and the Cux-1(C) virus to replicate in the MSB1 sublines clearly indicated that biological differences exist between the isolates. To determine the underlying basis for these differences, sequence analysis was performed on infectious molecular clones of Cux-1(C) and CIA-1. Comparison of the Cux-1(C) sequence with the published Cux-1(N) sequence (14) revealed seven nucleotide changes that presumably occurred during passage in culture. These changes resulted in four predicted amino acid differences in VP1 (Fig. 2) , one difference in VP2 [Cux(N), E-175 3 Cux(C), G-175], and one difference in VP3 [Cux(N), K-116 3 Cux(C), R-116]. The sequence of pCIA-1 revealed 42 differences from that of pCux-1(C). Within the coding regions, nine amino acid differences were predicted in VP1 (Fig. 2) , one difference was predicted in VP3 [Cux-1(C), R-118 3 CIA-1, C-118], and two differences were predicted in VP2 [Cux-1(C) A-153 3 CIA-1, V-153; Cux-1(C), G-175 3 CIA-1, E-175] (Fig. 3) . At only one position (nucleotide 371) does a single nucleotide change result in an amino acid change in an overlapping ORF (VP3, C-118 and VP2, V-153). Kato et al. (9) have reported a fourth ORF in the CAA82-2 isolate that is not found in Cux-1 isolates. CIA-1 also lacks an initiation codon for a fourth ORF. Six nucleotide differences within the noncoding regions did not alter any of the characterized regulatory motifs (13, 14) . The CIA-1 promoter region contains only four direct repeats in contrast to the five repeats found in Cux-1(C). Evidence indicates that the wild-type configuration is four repeats, and in some isolates a fifth repeat has been selected for by repeated passage in culture (13, 24) . This results in an overall length of 2,298 bp for CIA-1 in comparison with 2,319 bp for Cux-1(C). The ORF1 nucleotide sequences of the L-028 and ConnB strains were also compared with those of Cux-1(C). ConnB ORF1 had 10 differences in the coding region, which resulted in eight amino acid differences, and L-028 ORF1 had 48 nucleotide differences, which resulted in eight predicted VP1 differences (Fig.  2) .
Predicted amino acid sequences were also compared with sequences for other CIAV isolates, including Cux-1(M) (13), 26P4 (5), and CAA82-2 (9). Alignments of the sequences of VP2 and VP3 identified only scattered differences; no positions or domains displaying consistent variability could be identified. VP1 comparisons, however, revealed a previously unreported hypervariable region from amino acids 139 to 151 (Fig. 2) . Side group types within this region are mostly conserved and fall within a hydrophilic domain of the protein. Amino acid position 144 shows the greatest potential for variability and is the only location where four different substitutions are found. Additional regions of VP1 which have some degree of variability include the amino-terminal region spanning amino acids 2 to 29, with six differences between isolates, and the region spanning amino acids 248 to 254, with variation at three positions, all of which are common to more than one clone. Other regions of VP1 are highly conserved, with only scattered differences. Secondary structure plots (4) predict the hydrophilic cluster at amino acids 139 to 155 to have an alpha-helical structure. A difference in secondary structures between Cux-1 (C) and CIA-1 was not predicted, but a minor shift in hydrophilicity was indicated.
Transfection of MSB1(S) with CIAV chimeras. Transfection of MSB1(S) with plasmid clones of CIA-1 and Cux-1(C) resulted in patterns of infection that were similar to those observed in virion-initiated infections (Fig. 4) . This indicated that the infectious molecular clones that were isolated reflect the cytopathic characteristics of the Cux-1(C) and CIA-1 virus isolates. Two sets of chimeras (Fig. 3) were transfected to determine if differences in VP1 of CIA-1 are associated with differences in the rate of virus spread. Replacement of a 316-bp region of CIA-1 with that of Cux-1(C) (NheI replaced with BamHI) results in a Cux-1(C)-type infection, indicating that the hypervariable region contains the primary determinant affecting the rate of spread in MSB1(S) cultures (Fig. 4) . This conclusion is supported by the finding that the reciprocal Cux/ CIA N-B construct produces an infection profile more typical of CIA-1. However, we also noted that percentages of VP3-positive cells increased somewhat more rapidly with Cux/CIA N-B and Cux/CIA S-B than with CIA-1, suggesting that additional differences, either those downstream in VP1 or the single-nucleotide-induced change in VP2 and VP3 (V-153 and C-118), may have a secondary effect on the progression of infection.
Transfection of MSB1(L) cells. In several attempts to transfect MSB1(L) cells with the chimeras shown in Fig. 3 , only transfection with CIA/Cux S-B resulted in productive infections (data not shown). This indicated that the NheI-BamHI region was insufficient and that additional differences in the SacI-NheI region were required to support replication. How- ever, these results were equivocal in that they did not rule out the possibility that a difference(s) in the SacI-NheI region alone was capable of producing a replication-competent chimera. A second set of chimeras (Fig. 5 ) was constructed to more accurately define the region of interest and to attempt to identify secondary mediators of cytopathogenicity. The sequences of all chimeras were verified throughout the switched regions, and all were tested for replication competence by transfection into MSB1(S) cells. The successful transfection of MSB1(L) cells was verified by the observance of VP3-positive cells at 60 h posttransfection (Fig. 5) ; however, in many cases antigen expression was transient and productive infections were not established. None of the chimeras containing portions of the CIA-1 genome depicted in the top half of Fig. 5 was able to initiate infections in MSB1(L) cells. This confirms that the expression of VP1 regions of CIA-1 is sufficient to block replication and/or reinfection.
The chimeras in which portions of the CIA-1 genome were replaced with Cux-1(C) are depicted in the bottom half of Fig.  5 . All were able to initiate infections except Cux/CIA K-N, indicating that the expression of Cux-1(C) sequences downstream of the NheI site is insufficient to produce a construct capable of initiating infection in MSB1(L) cells and that an amino acid difference(s) within the SacI-NheI region is required. Therefore, the minimal amount of genetic information necessary to allow replication and/or reinfection, as determined by this method, is the entire SacI-BamHI region. This contrasts with the finding that the NheI-BamHI region alone contains the primary mediator of cytopathogenic potential in MSB1(S) cells.
Localization of VP3.
Comparison of the properties of the CIA/Cux B-S and CIA/Cux S-S chimeras indicates that CIA/ Cux S-S, which differs by a 222-nucleotide sequence containing only the CIA-1 V-153 and C-118 differences, spreads in culture less efficiently than CIA/Cux B-S. Infection of MSB1(S) cells with these chimeras produced similar results (results not shown). We had previously observed that the immunofluorescent staining patterns obtained with the VP3-specific monoclonal antibody 51.3 (3) suggested a different distribution of VP3 in Cux-1(C)-and CIA-1-infected cells. The same pattern was also observed in a comparison of CIA/Cux B-S and CIA/ Cux S-S in both MSB1(S) and MSB1(L) cells. The immunofluorescent staining pattern produced by CIA/Cux B-S is typical of Cux-1-like infections that show specific nuclear fluorescence with apoptotic bodies and relatively low levels of cytoplasmic fluorescence (Fig. 6A) . In contrast, cells infected with CIA/Cux S-S or CIA-1 display a more diffuse VP3-specific fluorescence with an increased cytoplasmic signal and a general lack of apoptotic bodies (Fig. 6B) . Interestingly, the difference in VP3 [Cux-1(C), R-118 3 CIA-1, C-118] falls within a group of 3 basic amino acids within a region reported to direct the nuclear localization of VP3 (16, 30) . It therefore seems plausible that the altered distribution of VP3 observed in CIA-1 and in all other chimeras containing this region (data not shown) can affect the replication of the virus. However, since the Cux-1, A-153 3 CIA-1, V-153 change in VP2 is caused by the same nucleotide substitution, we cannot rule out the possibility that VP2 is involved.
DISCUSSION
The findings presented here show that transformed avian lymphoblastoid cell lines vary in their susceptibilities to infection with different CIAV isolates and that differences in isolates can affect both the ability to replicate and the rate of replication in individual sublines. In culture the association of VP1 Q-139 and/or Q-144 with a decreased rate of spread is clear from the analysis of the chimeras containing only this region of CIA-1. What is less clear is which of the five amino acids upstream of the hypervariable region (VP1, N-23, I-75, Y-93, and L-97; VP2, E-175) are involved in the block of infection in some cell lines normally considered to be CIAV permissive. Further experiments using site-directed mutagenesis will be necessary to resolve the relationship between these amino acids and the hypervariable region, which likely involves a conformational change in VP1 or possibly an interaction between VP1 and VP2.
While this analysis most importantly shows that biological differences exist among CIAV isolates, we have been unable to demonstrate differences in host pathogenesis because of governmental restrictions against the use of the Cux-1(C) isolate in vivo which were a condition of the import permit. Comparative pathogenic analyses of CIAV isolates has been limited to examination of a few culture-passaged strains. Yuasa and Imai (29) identified subtle differences in pathogenicity between the Gifu-1 and A2 strains on the basis of age-related resistance to infection; however, there are currently no reports of comparisons between non-culture-passaged isolates, molecularly cloned isolates, or isolates that show readily identifiable differences in culture.
The finding of a variable region in VP1 of CIAV has been shown following the sequencing of three isolates from the United States and one isolate from Japan (9), thus indicating that isolates with the described variations are not geographically confined. Our analysis continues to support previous findings that CIAV isolates show little divergence in most coding regions. We note, for example, that CIA-1 and L-028 differ at 42 nucleotide positions in ORF1, but this results in only four predicted amino acid differences. Even so, it is possible that other regions of variability exist that will surface only as additional field isolates are examined. There is considerable evidence that CIAV mutates during passage in culture. Both our Cux-1(C) isolate and the Cux-1(M) (13) isolate have a number of differences compared with Cux-1(N) (14) . There is currently no evidence to suggest, however, that differences examined in this study are selected for by passage in culture. Recently Todd et al. (23) reported changes in the genetic composition of Cux-1 that could be monitored by restriction endonuclease analysis of PCR products obtained at increasing passage numbers. Restriction site differences found with the enzymes HpaII and HaeIII and with HinfI in a related study (24) cannot be correlated with differences in CIA-1, L-028, or ConnB. Sequence analysis of the culture-attenuated viruses (23) will be of great interest to see if the regions identified in this study can be associated with in vivo pathogenesis.
In addition to possible differences in pathogenic potential, the examination of variation among isolates may also be useful in the development of vaccines. Koch et al. (10) found that the simultaneous expression of VP1 and VP2 is required to induce neutralizing antibodies against Cux-1. The neutralizing epitope(s) has not been identified, but the observation of differences in VP1 may indicate a need for protection against a range of isolates. Another important question that will require clarification is the determination of the stage at which CIA-1 infection is blocked in MSB1(L) cells. An understanding of this mechanism may allow us to determine if specific erythroblastoid or T-cell populations in birds are naturally resistant.
